1 citations
,
October 2008 in “Urology” PSA levels help determine prostate size and guide treatment choices for benign prostatic hyperplasia.
1 citations
,
February 2008 in “Nature Clinical Practice Urology” Finasteride's sexual side effects may be due to nocebo effect.
1 citations
,
October 2006 in “Urology” Alpha-blocker therapy may not be needed long-term when combined with finasteride for BPH.
1 citations
,
December 2005 in “The Journal of Urology” Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.
1 citations
,
January 2004 in “Medicina de Familia SEMERGEN” Finasteride may help prevent prostate cancer.
1 citations
,
March 1997 in “Journal of Chromatography B: Biomedical Sciences and Applications” Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.
July 2026 in “Journal of the American Academy of Dermatology” Finasteride may lower depression risk in younger men with hair loss but increase it in older men with prostate issues.
June 2026 in “World Journal of Urology” Long-term finasteride use may lead to earlier use of ED medication and lower prostate cancer diagnosis rates.
May 2026 in “International Journal of Scientific Research in Chemistry” Finasteride breaks down into new compounds under acidic conditions.
May 2026 in “Reactions Weekly” Finasteride and dutasteride may increase the risk of suicide and sexual dysfunction.
April 2026 in “Journal of Clinical Medicine” Stopping finasteride can lead to lasting sexual and psychological issues.
March 2026 in “International Journal of Pharmaceutics and Drug Analysis” A reliable, cost-effective method was developed for accurately measuring finasteride in medicines.
March 2026 in “RS Global journals (RS Global Sp. z O.O.)” Finasteride is effective for hair loss and prostate issues but may cause lasting side effects.
These medications for BPH have known risks and may have new side effects.
These medications for BPH have known risks and may have new side effects.
March 2026 in “The Aging Male” PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
March 2026 in “Journal of Multidisciplinary Applied Natural Science” Cosmos caudatus extract is as effective as finasteride for treating benign prostatic hyperplasia without its side effects.
March 2026 in “Gazzetta Medica Italiana Archivio per le Scienze Mediche” Finasteride effectively treats benign prostatic hyperplasia by reducing prostate size and improving urinary symptoms.
February 2026 in “Archiv Euromedica” Finasteride effectively treats male hair loss, with oral and topical forms improving hair growth, but oral use may have side effects.
February 2026 in “Case Reports in Dermatology” Finasteride can cause melasma, especially in people with darker skin.
Compounds in fluted pumpkin and African yam bean seed oils may help manage benign prostate hyperplasia.
January 2026 in “Food Science and Human Wellness” Krill oil may help reduce prostate enlargement and growth.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
January 2026 in “British Journal of Clinical Pharmacology” Serenoa repens may cause long-lasting sexual and psychiatric side effects.
January 2026 in “Yonsei Medical Journal” Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
December 2025 in “International Neurourology Journal” Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
December 2025 in “Instituto Politécnico do Porto” Patients with mood disorders using 5α-reductase inhibitors may have a higher risk of suicidal thoughts.